23:15 , Jul 13, 2017 |  BC Week In Review  |  Clinical News

Neurotech's NT-501 meets in Phase II for macular telangiectasia

Neurotech Pharmaceuticals Inc. (Cumberland, R.I.) reported data from a Phase II trial in 67 patients with macular telangiectasia showing that implanted Renexus (NT-501) met the primary endpoint of reducing progressive loss of photoreceptors from baseline...
07:00 , Jun 13, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) Ciliary neurotrophic factor (CNTF) In vitro studies...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Regeneron regulatory update

The University of California (San Francisco) received U.S. Patent No. 5,667,968 covering the use of ciliary neurotrophic factor ( CNTF) to treat retinal diseases such as retinitis pigmentosa and macular degeneration. REGN has an exclusive...
07:00 , Jun 24, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Ciliary neurotrophic factor (CNTF) A study in cell culture and in mice suggests...
07:00 , Apr 8, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology CNS disorders Not applicable In vitro and rodent studies identified triazine-based compounds that could trigger neurite growth...
08:00 , Mar 11, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Ciliary neurotrophic factor (CNTF) In vitro and rat studies suggest that transplanting oligodendrocyte...
08:00 , Jan 7, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage Suppressor of cytokine signaling 3 (SOCS3); ciliary neurotrophic factor (CNTF) Studies in mice suggest that...
07:00 , Sep 24, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Retinitis Rhodopsin (RHO;...
07:00 , Jun 1, 2009 |  BC Week In Review  |  Clinical News

NT-501: Phase II data

Data from a double-blind Phase II trial in 67 patients with early stage RP showed that the high dose NT-501 implant led to a dose-dependent increase in retinal thickness from baseline to month 12 (p<0.001)....
07:00 , Jun 1, 2009 |  BC Week In Review  |  Clinical News

NT-501: Phase II data

Data from a double-blind Phase II trial in 65 patients with late-stage RP showed that the high dose NT-501 implant led to a dose-dependent increase in retinal thickness from baseline to month 12 (p<0.001). At...